Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SID1903-R1 + SID1903-R2** is a combination of two investigational formulations of the drug SID1903, used in pharmacokinetic studies to assess and compare the safety and pharmacokinetic profiles against the fixed dose combination (FDC) product SID1903. SID1903 itself is a fixed dose combination of **dapagliflozin** (a sodium-glucose co-transporter 2 (SGLT2) inhibitor) and **sitagliptin** (a dipeptidyl peptidase-4 (DPP-4) inhibitor), both of which are oral antidiabetic agents primarily indicated for the management of type 2 diabetes mellitus. The specific composition or role of SID1903-R1 and SID1903-R2 is not detailed beyond being comparator formulations to the fixed combination; both are administered orally in healthy adult volunteers for pharmacokinetic evaluation in clinical studies[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SID1903-R1 + SID1903-R2.